Innervate Radiopharmaceuticals Llc (formerly: Illumina Radiopharmaceuticals Llc)
Clinical trials sponsored by Innervate Radiopharmaceuticals Llc (formerly: Illumina Radiopharmaceuticals Llc), explained in plain language.
-
New PET tracer aims to reveal hidden heart nerve damage
Diagnosis OngoingThis early-phase trial tests a radioactive imaging agent called 18F-mFBG to see how well it can show the nerves in the heart. Researchers will give the agent to 10 adults—some with heart disease and some without—and take PET scans over time. The goal is to measure how the agent m…
Phase: PHASE1, PHASE2 • Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New PET scan agent could spot childhood cancer more clearly
Diagnosis OngoingThis Phase 3 trial tests a radioactive imaging agent called 18F-mFBG to see if it can accurately detect neuroblastoma, a type of childhood cancer. The study involves 43 participants who either have or are suspected of having neuroblastoma. Researchers will compare the new PET sca…
Phase: PHASE3 • Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC